Article: Results of Sepracor's LUNESTA(R) Next-Day Driving Study in Patients with Primary Insomnia Presented at American College of Neuropsychopharmacology Meeting.(Clinical report)

Article: Effects of Varying Levels of Physical Activity on [VO.sub.2]max ...
Research Quarterly for Exercise and Sport;  March 1, 2001 ;     700+ words ... ... activity on various aspects of [VO.sub.2]max and psychomotor function of older men. Participants were between 60 and 70 years ... somewhat surprisingly on the basis of previous research, psychomotor function did not appear to be impacted by physical activity levels ...

Article: Perinatal exposure to vigabatrin impairs psychomotor ...
Pain & Central Nervous System Week;  August 16, 2004 ;     700+ words ... ... International Journal of Developmental Neuroscience (Perinatal exposure to GABA-transaminase inhibitor impaired psychomotor function in the developing and adult mouse. Int J Dev Neurosci, 2004;22(3):137-147). For more information ...

Article: Total intravenous versus inhalational anaesthesia for colonscopy: ...
Anaesthesia and Intensive Care;  April 1, 2001 ;     700+ words ... ... midazolam/propofol combination. We studied the immediate emergence parameters and the time-course of recovery of psychomotor function, which relate to patient "home-readiness", "street-fitness" and driving ability. MATERIALS AND METHODS ...

Article: The rotary pursuit test is not an index of normal ...
Military Medicine;  August 1, 2001 ;     700+ words ...Objective: This study sought to assess whether the rotary pursuit test is a good indication of the psychomotor performance of human subjects during normal working hours. Circadian hormonal profiles of salivary melatonin and cortisol were also established for correlation with performance. Methods:

Article: LUNESTA(TM) Brand Eszopiclone, Formerly ESTORRA, Approved ...
PR Newswire;  December 16, 2004 ;     700+ words ... ... approved the New Drug Application (NDA) for LUNESTA(TM) brand eszopiclone, formerly referred ... for the FDA's decision to not limit LUNESTA's indication to short-term use. Sepracor ... study with no evidence of tolerance." LUNESTA is indicated for the treatment of patients ...

Article: LUNESTA(TM) Now Widely Available by Prescription to Treat ...
PR Newswire;  April 7, 2005 ;     700+ words ... ... Sepracor Inc. today announced that LUNESTA(TM) (eszopiclone 1 mg, 2 mg and 3 ... prescription in most pharmacies nationwide. LUNESTA is the first and only sleep aid (prescription ... for long-term treatment of insomnia. LUNESTA is the first treatment in its class that ...

Article: LUNESTA(TM) Perimenopause-Menopause Study Data to Be ...
Business Wire;  September 30, 2005 ;     700+ words ... ... study evaluating safety and efficacy of LUNESTA(TM) brand eszopiclone for treatment ... placebo-controlled study, nightly use of LUNESTA 3 mg resulted in statistically significant ... treatment period. Patients treated with LUNESTA also demonstrated significant improvements ...